Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
about
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.Features of occult invasion in biopsy-proven DCIS at breast MRI.Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.Regression of ductal carcinoma in situ after treatment with acupunctureBiological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.Progression of Ductal Carcinoma in Situ from the Pathological Perspective.Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatmentDuctal carcinoma in situ: treatment or active surveillance?Ductal Carcinoma In Situ: Treatment Update and Current Trends.Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia.Pathology of healing: what else might we look at?Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance.Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast.
P2860
Q30436536-090030B4-1E09-4B09-9E71-DD54FE6C635FQ33677927-95C16C1F-DDC5-4C02-A05B-64ADD0E2FE91Q33864861-B2148C2F-2992-49B1-A900-B4B288A0A2E6Q33984087-BB7070EE-A62E-4110-BAF4-05713724566FQ34335729-7AA0AD49-394C-4FA2-9F10-5392860B3E45Q34940834-3BF4E379-02EA-40AB-AD76-12EC0A52D989Q35899068-423E5D8D-5311-4819-99B0-6825396B8EC1Q35940085-10025ABA-E08B-4840-B3AA-528043500585Q37003317-91440EC9-243C-4A78-BC2C-16E89BC17F81Q38457619-43C60A17-0907-42EF-9A83-5C6601FC06B1Q38587441-733C6DDC-C584-4415-B476-DC785D3397C7Q38802962-4C202673-C3C5-4FF9-9D6A-FA8900E35134Q38805491-04A69B6C-4870-4813-AAF3-550DCA903673Q43107258-4E313213-A174-4FA3-9DDE-F6868A6F29A2Q50938248-4B035B67-BAFB-4B72-AA5C-5C95882A3159Q53723597-31CC8D96-534A-483D-A874-54D4B5702153
P2860
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pathologic and biologic respon ...... tive ductal carcinoma in situ.
@ast
Pathologic and biologic respon ...... tive ductal carcinoma in situ.
@en
type
label
Pathologic and biologic respon ...... tive ductal carcinoma in situ.
@ast
Pathologic and biologic respon ...... tive ductal carcinoma in situ.
@en
prefLabel
Pathologic and biologic respon ...... tive ductal carcinoma in situ.
@ast
Pathologic and biologic respon ...... tive ductal carcinoma in situ.
@en
P2093
P2860
P356
P1433
P1476
Pathologic and biologic respon ...... itive ductal carcinoma in situ
@en
P2093
E Shelley Hwang
Frederic M Waldman
Joseph Anderson
Juan Lessing
Laura J Esserman
Rebecca Swain
Sandy DeVries
Yunn-Yi Chen
P2860
P2888
P356
10.1186/1471-2407-9-285
P407
P50
P577
2009-08-18T00:00:00Z
P5875
P6179
1048041962